Michael Wang, MD, highlights ASH 2025 data showing how continual innovation across targeted agents, cellular and immune therapies—paired with MRD monitoring and intensified maintenance strategies—is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results